COYA: Utang jangka cendhak perusahaan Coya Therapeutics, Inc.

Coya Therapeutics, Inc. (COYA) relies on contract manufacturing for its drugs, focusing on R&D and exosome patents. The company's short-term debt on the chart demonstrates liability dynamics, where the indicator stands at 0.00. The business's financial stability depends on external funding and clinical trials. Currently, Coya Therapeutics, Inc. (COYA) is developing an innovative T-cell therapy to combat neurodegeneration and systemic inflammation in ALS.

This indicator aggregates all liabilities with a maturity of less than twelve months, determining the capital structure's sensitivity to borrowing costs. For Coya Therapeutics, Inc. (COYA), which generates no revenue and depends on FDA approvals, short-term debt with a maturity of up to one year becomes a critical marker of solvency amid high clinical trial risks and a lack of operating income.